A Phase 1/1b First-in-human Study of BMS-986463 in Advanced Malignant Tumors
Status: Recruiting
Location: See all (17) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.
• Participants must have at least 1 lesion accessible for biopsy in addition to the target lesion, from which a fresh pre treatment biopsy must be obtained.
• Participants must have an unresectable/metastatic carcinoma.
Locations
United States
California
USC/Norris Comprehensive Cancer Center
RECRUITING
Los Angeles
Valkyrie Clinical Trials
RECRUITING
Los Angeles
New Jersey
John Theurer Cancer Center at Hackensack University Medical Center
RECRUITING
Hackensack
Ohio
Local Institution - 0045
NOT_YET_RECRUITING
Columbus
Texas
Local Institution - 0046
NOT_YET_RECRUITING
Dallas
Local Institution - 0049
NOT_YET_RECRUITING
Houston
Other Locations
Canada
Centre Hospitalier de l'Université de Montréal
RECRUITING
Montreal
Jewish General Hospital
RECRUITING
Montreal
Princess Margaret Cancer Centre
RECRUITING
Toronto
BC Cancer Vancouver
RECRUITING
Vancouver
France
Local Institution - 0036
NOT_YET_RECRUITING
Bordeaux
Local Institution - 0035
NOT_YET_RECRUITING
Lyon
Local Institution - 0031
NOT_YET_RECRUITING
Villejuif
Italy
Local Institution - 0032
NOT_YET_RECRUITING
Milan
Local Institution - 0033
NOT_YET_RECRUITING
Milan
Spain
Local Institution - 0041
NOT_YET_RECRUITING
Avda.pio Xii 36,
Local Institution - 0042
NOT_YET_RECRUITING
Barcelona
Contact Information
Primary
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Clinical.Trials@bms.com
855-907-3286
Backup
First line of the email MUST contain NCT # and Site #.
Time Frame
Start Date: 2024-09-06
Estimated Completion Date: 2028-12-19
Participants
Target number of participants: 240
Treatments
Experimental: Arm 1: Dose Escalation
Experimental: Arm 2: Dose Expansion
Related Therapeutic Areas
Sponsors
Leads: Bristol-Myers Squibb